

FITC anti-mouse IgD Antibody

Catalog# / Size	405703 / 50 µg 405704 / 500 µg
Clone	11-26c.2a
Regulatory Status	RUO
Other Names	Immunoglobulin D
Isotype	Rat IgG2a, κ
Description	Surface IgD is an important B cell differentiation marker.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm)
Application Notes	The 11-26c.2a antibody reacts with immunoglobulin D in all tested mouse haplotypes. The antibody binds membrane IgD expressed on most B cells. The 11-26c.2a antibody neither induces proliferation of splenic B cells nor induces B cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections ^{2,3} , and spatial biology (IBEX) ^{10,11} .
Application References	<ol style="list-style-type: none"> 1. Nitschke L, <i>et al.</i> 1993. <i>P. Natl. Acad. Sci. USA</i> 90:1887. (FC) 2. Weih D, <i>et al.</i> 2001. <i>J. Immunol.</i> 167:1909. (IHC) 3. Koni PA, <i>et al.</i> 2001. <i>J. Exp. Med.</i> 193:741. (IHC) 4. Ahuja A, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:3351. (FC) PubMed 5. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC) 6. Good-Jacobson KL, <i>et al.</i> 2010. <i>Nat. Immunol.</i> 11:535. (FC) PubMed 7. Tomayko MM, <i>et al.</i> 2010. <i>J. Immunol.</i> 185:7146. PubMed 8. Park SY, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:1094. PubMed 9. Rouaud P, <i>et al.</i> 2014. <i>J Exp Med.</i> 211:975. PubMed 10. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed 11. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed

Product Citations

1. Rydzynski CE *et al.* 2018. *Cell reports.* 24(13):3367-3373 . [PubMed](#)
2. Xu Y, *et al.* 2022. *Nat Commun.* 13:980. [PubMed](#)
3. Sweet R, *et al.* 2011. *Proc Natl Acad Sci U S A.* 108:7932. [PubMed](#)
4. Schiller M, *et al.* 2021. *Immunity.* 54(5):1022-1036.e8. [PubMed](#)
5. Inoue D, *et al.* 2021. *Nat Genet.* 53:707. [PubMed](#)
6. Parthasarathy R, *et al.* 2021. *Front Immunol.* 12:758407. [PubMed](#)

7. Duan L, *et al.* 2021. *Immunity*. 54:2256. [PubMed](#)
8. Mintz MA, *et al.* 2019. *Immunity*. 51:310. [PubMed](#)
9. Liu X, *et al.* 2022. *Nat Cancer*. :. [PubMed](#)
10. Zheng S, *et al.* 2019. *PLoS Biol*. 17:e3000569. [PubMed](#)
11. Chiu Y, *et al.* 2014. *J Immunol*. 193:2207. [PubMed](#)
12. Gironi M, *et al.* 2021. *Blood Adv*. 5:2817. [PubMed](#)
13. Suan D *et al.* 2017. *Immunity*. 47(6):1142-1153 . [PubMed](#)
14. Souza SP, *et al.* 2021. *PLoS Pathog*. 17:e1010081. [PubMed](#)
15. Adachi Y, *et al.* 2019. *Nat Commun*. 10:3883. [PubMed](#)
16. Sanchez HN, *et al.* 2020. *Nat Commun*. 0.5. [PubMed](#)
17. Omatsu Y, *et al.* 2022. *Nat Commun*. 13:2654. [PubMed](#)
18. Yasuda S, *et al.* 2018. *Genes Cells*. 23:868. [PubMed](#)
19. Ryg-Cornejo V, *et al.* 2016. *Cell Rep*. 14:68-81. [PubMed](#)
20. Gawish R, *et al.* 2022. *Elife*. 11:. [PubMed](#)
21. Pessoa Rodrigues C, *et al.* 2020. *Sci Adv*. 6:eaaz4815. [PubMed](#)

RRID AB_315025 (BioLegend Cat. No. 405703)
 AB_315026 (BioLegend Cat. No. 405704)

Antigen Details

Structure	Ig family
Distribution	B cells
Function	B cell differentiation
Cell Type	B cells
Biology Area	Immunology
Gene ID	380797


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

FITC anti-mouse IgD, PE anti-mouse IgD, Purified anti-mouse IgD, PerCP anti-mouse IgD, Biotin anti-mouse IgD, Brilliant Violet 711™ anti-mouse IgD, Alexa Fluor® 700 anti-mouse IgD, Alexa Fluor® 647 anti-mouse IgD, PerCP/Cyanine5.5 anti-mouse IgD, Pacific Blue™ anti-mouse IgD, APC anti-mouse IgD, APC/Cyanine7 anti-mouse IgD, Alexa Fluor® 488 anti-mouse IgD, PE/Cyanine7 anti-mouse IgD, Brilliant Violet 650™ anti-mouse IgD, Brilliant Violet 510™ anti-mouse IgD, Brilliant Violet 421™ anti-mouse IgD, Brilliant Violet 605™ anti-mouse IgD, Purified anti-mouse IgD (Maxpar® Ready), Alexa Fluor® 594 anti-mouse IgD, PE/Dazzle™ 594 anti-mouse IgD, APC/Fire™ 750 anti-mouse IgD, TotalSeq™-A0571 anti-mouse IgD, TotalSeq™-C0571 anti-mouse IgD, Spark NIR™ 685 anti-mouse IgD, TotalSeq™-B0571 anti-mouse IgD Antibody, Spark Violet™ 423 anti-mouse IgD, PE/Cyanine5 anti-mouse IgD

Product Data



C57BL/6 mouse splenocytes stained with 11-26c.2a FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587